54582-58-0

Upstream product

• 1493-27-2 ortho-nitrofluorobenzene 
• 88-73-3 2-Chloronitrobenzene 
• 150-76-5 4-methoxy-phenol 
• 58656-16-9 2-(4-methoxyphenoxy)nitrobenzene 

Downstream Products

• 5535-22-8 4-(2-aminophenoxy)phenol 
• 121332-08-9 4-(2-Nitrophenoxy)phenyl 2-(4-(4-chlorophenoxy)phenoxy) propionate 
• 1256264-22-8 2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenoxy)aniline 
• 1256333-84-2 N-(methylsulfonyl)-N-(2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenoxy)phenyl)methanesulfonamide 
• 1256264-05-7 1-(2-(4-(2-nitrophenoxy)phenoxy)ethyl)pyrrolidine 
• 1422539-06-7 C₂₉H₃₁N₃O₇ 
• 1422539-10-3 C₂₄H₂₃N₃O₅*ClH 
• 1450804-86-0 1-(4-(2-chloroethoxy)phenoxy)-2-nitrobenzene 
• 1450804-85-9 1-(4-(3-chloropropoxy)phenoxy)-2-nitrobenzene 
• 1450804-91-7 (R)-2-methyl-1-(2-(4-(2-nitrophenoxy)phenoxy)ethyl)pyrrolidine 
• 1450804-90-6 (R)-2-methyl-1-(3-(4-(2-nitrophenoxy)phenoxy)propyl)pyrrolidine 
• 1610838-94-2 (R)-2-methyl-1-(2-(5-(2-nitrophenoxy)benzofuran-2-yl)ethyl)pyrrolidine 
• 1610838-91-9 2-iodo-4-(2-nitrophenoxy)phenol 

Relevant academic research and scientific papers

NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

A compound of formula (I) : wherein Z, Y1,Y2,(Formula II)R1 to R7 are as defined in the description, its optical isomers, and addition salts thereof with a pharmaceutically acceptable base. Medicaments.

Synthesis and biological evaluation of XB-1 analogues as novel histamine H3 receptor antagonists and neuroprotective agents

A novel class of H3 receptor antagonists, XB-1 analogues based on benzophenone or oxydibenzene scaffolds were synthesized, and their biological activities were evaluated to determine their in vitro neuroprotective effects against Aβ25-35-induced damage in primary cortical neurons and against glutamate-induced neuronal injury in primary cerebellar granule neurons. The results indicated that all of the tested analogues displayed neuroprotective activity at 0.1 μM or 1 μM. These findings may provide new insights into the development of novel promising H3 receptor antagonists with potential neuroprotective activity.

Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase

Dual function inhibitors targeting phospholipase A2 (PLA 2) and leukotriene A4 hydrolase (LTA4H) may balance the arachidonic acid (AA) metabolic network and be used as new anti-inflammatory drugs. In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (JMC08-4) for human nonpancreatic secretory phospholipase A2 (hnps-PLA 2) and human leukotriene A4 hydrolase (LTA4H-h) was found. Based on the structure of compound JMC08-4, new dual-target inhibitors were designed assisted by molecular docking. In this report, a series of 5-hydroxytryptamine compounds were synthesized; and most of these title compounds showed more potent inhibitory activity than compound JMC08-4 in the in vitro bioassay against these two enzymes. The best one inhibited hnps-PLA 2 and LTA4H-h with IC50 values of 9.2 ± 0.5 μM and 2.4 ± 1.4 μM, respectively.

Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase

Dual target inhibitors against COX-2 and LTA4H were designed by adding functional groups from a marketed COX-2 inhibitor, Nimesulide, to an existing LTA4H inhibitor 1-(2-(4-phenoxyphenoxy) ethyl) pyrrolidine. A series of phenoxyphenyl pyrrolidine compounds were synthesized and tested for their inhibition activities using enzyme assays and human whole blood assay. Introduction of small electron withdrawing groups like NO2 and CF3 in the ortho-position of the terminal phenyl ring was found to change the original single target LTA4H inhibitor to dual target LTA4H and COX-2 inhibitors. Compound 5a and 5m showed dual LTA 4H and COX-2 inhibition activities in the enzyme assays and the HWB assay with IC50 values in the micromolar to submicromolar range. As their activities in HWB assay were comparable to the two starting single target inhibitors, the two compounds are promising for further studies. The strategy used in the current study may be generally applicable to other dual target drug designs.

4-Hydroxy-2'-nitrodiphenyl ether analogues as novel tyrosinase inhibitors

Tyrosinase ubiquitously existing from microorganisms to animals and plants is known to be the most critical and rate limiting enzyme during melanin biosynthesis. In order to develop new tyrosinase inhibitor we have synthesized 14 diphenyl ether compounds

2-Phenoxyaniline derivatives

PCT No. PCT/JP98/04729 Sec. 371 Date Apr. 10, 2000 Sec. 102(e) Date Apr. 10, 2000 PCT Filed Oct. 20, 1998 PCT Pub. No. WO99/20598 PCT Pub. Date Apr. 29, 1999A 2-phenoxyaniline derivative represented by the formula: wherein R1 is a hydrogen atom or a lower alkoxy group, R2 is a halogen atom or a nitro group, and R3 is a hydrogen atom or a halogen atom, or a pharmaceutically acceptable salt thereof.